DIA 2023: Venkatraman Balasubramanian Discusses Audience Feedback During His "The Case for Generating Synthetic Data as Real-World Data: Regulatory and Planning Perspectives” Presentation

Breakout session discusses the impact of incorporating decentralized elements into oncology clinical trials on data integrity, patient safety, and regulatory approvals.

Session highlights the value of simulations such as data analysis and endpoint selection in clinical development.

Trial shows Keytruda improved overall survival by 38% compared with placebo in in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions.

Satri-cel (satricabtagene autoleucel) showed a promising safety and efficacy profile in patients with gastric or gastroesophageal cancer and pancreatic cancer.

Fathallah shares his thoughts on the recent DIA 2023 Annual Meeting in Boston, MA.

Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research.